452. Lin, Y.S.; Shaw, A.Y.; Wang, S.G.; Hsu, C.C.; Teng, I.W.; Tseng, M.J.; Huang, T.H.; Chen, C.S.; Leu, Y.W.; Hsiao, S.H. Identification of novel DNA methylation inhibitors via a two-component reporter gene system. *J. Biomed. Sci.* **2011**, *18*, 3. [CrossRef]

453. Teng, I.W.; Hou, P.C.; Lee, K.D.; Chu, P.Y.; Yeh, K.T.; Jin, V.X.; Tseng, M.J.; Tsai, S.J.; Chang, Y.S.; Wu, C.S.; et al. Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells. *Cancer Res.* **2011**, *71*, 4653–4663. [CrossRef] [PubMed]

454. Berdasco, M.; Fraga, M.F.; Esteller, M. Quantification of global DNA methylation by capillary electrophoresis and mass spectrometry. In *DNA Methylation, Methods and Protocols*. Springer Protocols. Methods in Molecular Biology; Tost, J., Ed.; Humana Press: New York, NY, USA, 2009; Volume 507, pp. 23–34.

455. Fraga, M.F.; Uriol, E.; Borja, D.L.; Berdasco, M.; Esteller, M.; Canal, M.J.; Rodriguez, R. High-performance capillary electrophoretic method for the quantification of 5-methyl 2'-deoxycytidine in genomic DNA: Application to plant, animal and human cancer tissues. *Electrophoresis* **2002**, *23*, 1677–1681. [CrossRef]

456. Rocha, M.S.; Castro, R.; Rivera, I.; Kok, R.M.; Smulders, Y.M.; Jakobs, C.; de Almeida, I.T.; Blom, H.J. Global DNA methylation: Comparison of enzymatic- and non-enzymatic-based methods. *Clin. Chem. Lab. Med.* **2010**, *48*, 1793–1798. [CrossRef] [PubMed]

457. Kok, R.M.; Smith, D.E.; Barto, R.; Spijkerman, A.M.; Teerlink, T.; Gellekink, H.J.; Jakobs, C.; Smulders, Y.M. Global DNA methylation measured by liquid chromatography-tandem mass spectrometry: Analytical technique, reference values and determinants in healthy subjects. *Clin. Chem. Lab. Med.* **2007**, *45*, 903–911. [CrossRef] [PubMed]

458. Guo, M.; Li, X.; Zhang, L.; Liu, D.; Du, W.; Yin, D.; Lyu, N.; Zhao, G.; Guo, C.; Tang, D. Accurate quantification of 5-Methylcytosine, 5-Hydroxymethylcytosine, 5-Formylcytosine, and 5-Carboxylcytosine in genomic DNA from breast cancer by chemical derivatization coupled with ultra performance liquid chromatography- electrospray quadrupole time of flight mass spectrometry analysis. *Oncotarget* **2017**, *8*, 91248–91257.

459. Fernandez, A.F.; Valledor, L.; Vallejo, F.; Canal, M.J.; Fraga, M.F. Quantification of global DNA methylation levels by mass spectrometry. *Methods Mol. Biol.* **2018**, *1708*, 49–58.

460. Shahal, T.; Koren, O.; Shefer, G.; Stern, N.; Ebenstein, Y. Hypersensitive quantification of global 5-hydroxymethylcytosine by chemoenzymatic tagging. *Anal. Chim. Acta* **2018**, *1038*, 87–96. [CrossRef]

461. Meissner, A.; Gnirke, A.; Bell, G.W.; Ramsahoye, B.; Lander, E.S.; Jaenisch, R. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. *Nucleic Acids Res.* **2005**, *33*, 5868–5877. [CrossRef]

462. Gu, H.; Bock, C.; Mikkelsen, T.S.; Jager, N.; Smith, Z.D.; Tomazou, E.; Gnirke, A.; Lander, E.S.; Meissner, A. Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution. *Nat. Methods* **2010**, *7*, 133–136. [CrossRef]

463. Choudhury, S.R.; Walker, B.A. A rapid and robust protocol for reduced representation bisulfite sequencing in multiple myeloma. *Methods Mol. Biol.* **2018**, 1792, 179–191.

464. Karimi, M.; Johansson, S.; Stach, D.; Corcoran, M.; Grander, D.; Schalling, M.; Bakalkin, G.; Lyko, F.; Larsson, C.; Ekstrom, T.J. LUMA (LUminometric Methylation Assay)-a high throughput method to the analysis of genomic DNA methylation. *Exp. Cell Res.* **2006**, *312*, 1989–1995. [CrossRef] [PubMed]

465. Wang, S.C.; Petronis, A. DNA Methylation Microarrays, Experimental Design and Statistical Analysis; CRC Press: Boca Raton, FL, USA, 2008; pp. 1–256.

466. Esteller, M. DNA Methylation: *Approaches, Methods, and Applications*; CRC Press: New York, NY, USA, 2004; pp. 1–223.

467. Tost, J. DNA Methylation, Methods and Protocols, 2nd ed.; Humana Press: New York, NY, USA, 2009; pp. 1–356.

468. Noberini, R.; Restellini, C.; Savoia, E.O.; Bonaldi, T. Enrichment of histones from patient samples for mass spectrometry-based analysis of post-translational modifications. *Methods* **2019**, *184*, 19–28. [CrossRef] [PubMed]

469. Tan, D.; Chung, T.H.; Sun, X.; Jia, X.Y. Mirror bisulfite sequencing: A method for single-base resolution of hydroxymethylcytosine. *Anal. Chem.* **2018**, *90*, 13200–13206. [CrossRef] [PubMed]

470. Foksinski, M.; Zarakowska, E.; Gackowski, D.; Skonieczna, M.; Gajda, K.; Hudy, D.; Szpila, A.; Bialkowski, K.; Starczak, M.; Labejszto, A.; et al. Profiles of a broad spectrum of epigenetic DNA modifications in normal and malignant human cell lines: Proliferation rate is not the major factor responsible for the 5-hydroxymethyl-2'-deoxycytidine level in cultured cancerous cell lines. *PLoS ONE* **2017**, *12*, e0188856. [CrossRef] [PubMed]

471. Zeng, H.; He, B.; Xia, B.; Bai, D.; Lu, X.; Cai, J.; Chen, L.; Zhou, A.; Zhu, C.; Meng, H.; et al. Bisulfite-free, nanoscale analysis of 5-hydroxymethylcytosine at single base resolution. *J. Am. Chem. Soc.* **2018**, *140*, 13190–13194. [CrossRef] [PubMed]

472. Pogrebny, I.; Yi, P.; James, S.J. A sensitive new method for rapid detection of abnormal methylation patterns in global DNA and within CpG islands. *Biochem. Biophys. Res. Commun.* **1999**, *262*, 624–628. [CrossRef]

473. Lander, E.S.; Linton, L.M.; Birren, B.; Nusbaum, C.; Zody, M.C.; Baldwin, J.; Devon, K.; Dewar, K.; Doyle, M.; FitzHugh, W.; et al. Initial sequencing and analysis of the human genome. *Nature* **2001**, *409*, 860–921.

474. Karimi, M.; Johansson, S.; Ekstrom, T.J. Using LUMA: A Luminometric-based assay for global DNA-methylation. *Epigenetics* **2006**, *1*, 45–48.

475. Bielefeld-Sevigny, M. AlphaLISA immunoassay platform- the “no-wash” high-throughput alternative to ELISA. *Assay Drug Dev. Technol.* **2009**, *7*, 90–92. [CrossRef]

476. Song, Y.; Li, L.; Chen, Y.; Liu, J.; Xiao, S.; Lian, F.; Zhang, N.; Ding, H.; Zhang, Y.; Chen, K.; et al. Discovery of potent DOT1L inhibitors by AlphaLISA based high throughput screening assay. *Bioorg. Med. Chem.* **2018**, *26*, 1751–1758. [CrossRef] [PubMed]

477. Machleidt, T.; Rogers, M.B.; Hermanson, S.B.; Dudek, J.M.; Bi, K. TR-FRET cellular assays for interrogating posttranslational modifications of histone H3. *J. Biomol. Screen.* **2011**, *16*, 1236–1246. [CrossRef]
478. Fan, J.; Baeza, J.; Denu, J.M. Investigating histone acetylation stoichiometry and turnover rate. *Methods Enzymol.* **2016**, *574*, 125–148.

479. Simon, R.P.; Robaa, D.; Alhalabi, Z.; Sippl, W.; Jung, M. KATching-up on small molecule modulators of lysine acetyltransferases. *J. Med. Chem.* **2016**, *59*, 1249–1270. [CrossRef]

480. Esteller, M. Epigenetic lesions causing genetic lesions in human cancer: Promoter hypermethylation of DNA repair genes. *Eur. J. Cancer* **2000**, *36*, 2294–2300. [CrossRef]

481. Vos, S.; Van Diest, P.J.; Moelans, C.B. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not? *Crit. Rev. Oncol. Hematol.* **2018**, *127*, 29–41. [CrossRef]

482. Nguyen, Q.N.; Vuong, L.D.; Truong, V.L.; Ta, T.V.; Nguyen, N.T.; Nguyen, H.P.; Chu, H.H. Genetic and epigenetic alterations of the EGFR and mutually independent association with BRCA1, MGMT, and RASSF1A methylations in Vietnamese lung adenocarcinomas. *Pathol. Res. Pract.* **2019**, *215*, 885–892. [CrossRef]

483. Nakamura, K.; Saredi, G.; Becker, J.R.; Foster, B.M.; Nguyen, N.V.; Beyer, T.E.; Cesa, L.C.; Faull, P.A.; Lukauskas, S.; Frimurer, T.; et al. H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids. *Nat. Cell Biol.* **2019**, *21*, 311–318. [CrossRef]

484. Chatterjee, A.; Gupta, S. The multifaceted role of glutathione S-transferases in cancer. *Cancer Lett.* **2018**, *433*, 33–42. [CrossRef] [PubMed]

485. Cui, J.; Li, G.; Yin, J.; Li, L.; Tan, Y.; Wei, H.; Liu, B.; Deng, L.; Tang, J.; Chen, Y.; et al. GSTP1 and cancer: Expression, methylation, polymorphisms and signaling (Review). *Int. J. Oncol.* **2020**, *56*, 867–878. [CrossRef] [PubMed]

486. Tsuchida, S.; Sekine, Y.; Shineha, R.; Nishihira, T.; Sato, K. Elevation of the placental glutathione S-transferase form (GST-pi) in tumor tissues and the levels in sera of patients with cancer. *Cancer Res.* **1989**, *49*, 5225–5229. [PubMed]

487. Satoh, K.; Kitahara, A.; Soma, Y.; Inaba, Y.; Hatayama, I.; Sato, K. Purification, induction, and distribution of placental glutathione transferase: A new marker enzyme for preneoplastic cells in the rat chemical hepatocarcinogenesis. *Proc. Natl. Acad. Sci. USA* **1985**, *82*, 3964–3968. [CrossRef]

488. Jain, S.; Chen, S.; Chang, K.C.; Lin, Y.J.; Hu, C.T.; Boldbaatar, B.; Hamilton, J.P.; Lin, S.Y.; Chang, T.T.; Chen, S.H.; et al. Impact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinoma. *PLoS ONE* **2012**, *7*, e35789. [CrossRef]

489. Tian, M.; Peng, S.; Martin, F.L.; Zhang, J.; Liu, L.; Wang, Z.; Dong, S.; Shen, H. Perfluorooctanoic acid induces gene promoter hypermethylation of glutathione-S-transferase Pi in human liver L02 cells. *Toxicology* **2012**, *296*, 48–55. [CrossRef]

490. Alnaes, G.I.; Ronneberg, J.A.; Kristensen, V.N.; Tost, J. Heterogeneous DNA methylation patterns in the GSTP1 promoter lead to discordant results between assay technologies and impede its implementation as epigenetic biomarkers in breast cancer. *Genes* **2015**, *6*, 878–900. [CrossRef]

491. Beroukhim, R.; Mermel, C.H.; Porter, D.; Wei, G.; Raychaudhuri, S.; Donovan, J.; Barretina, J.; Boehm, J.S.; Dobson, J.; Urashima, M.; et al. The landscape of somatic copy-number alteration across human cancers. *Nature* **2010**, *463*, 899–905. [CrossRef]

492. Jiao, Y.; Feng, Y.; Wang, X. Regulation of tumor suppressor gene CDKN2A and encoded p16-INK4a protein by covalent modifications. *Biochemistry* **2018**, *83*, 1289–1298. [CrossRef]

493. Herman, J.G.; Merlo, A.; Mao, L.; Lapidus, R.G.; Issa, J.P.; Davidson, N.E.; Sidransky, D.; Baylin, S.B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. *Cancer Res.* **1995**, *55*, 4525–4530. [PubMed]

494. Fontana, R.; Ranieri, M.; La, M.G.; Vivo, M. Dual role of the alternative reading frame ARF protein in cancer. *Biomolecules* **2019**, *9*, 87. [CrossRef] [PubMed]

495. Inoue, K.; Fry, E.A. Aberrant expression of p14(ARF) in human cancers: A new biomarker? *Tumor Microenviron.* **2018**, *1*, 37–44. [CrossRef]

496. Garcia-Gutierrez, L.; Delgado, M.D.; Leon, J. MYC oncogene contributions to release of cell cycle brakes. *Genes* **2019**, *10*, 244. [CrossRef]

497. Krimpenfort, P.; IJpenberg, A.; Song, J.Y.; van der Valk, M.; Nawijn, M.; Zevenhoven, J.; Berns, A. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. *Nature* **2007**, *448*, 943–946. [CrossRef]

498. Kotake, Y.; Nakagawa, T.; Kitagawa, K.; Suzuki, S.; Liu, N.; Kitagawa, M.; Xiong, Y. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. *Oncogene* **2011**, *30*, 1956–1962. [CrossRef]

499. Kong, Y.; Hsieh, C.H.; Alonso, L.C. ANRIL: A lncRNA at the CDKN2A/B locus with roles in cancer and metabolic disease. *Front. Endocrinol.* **2018**, *9*, 405. [CrossRef]

500. Herman, J.G.; Jen, J.; Merlo, A.; Baylin, S.B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. *Cancer Res.* **1996**, *56*, 722–727.

501. Hinshelwood, R.A.; Melki, J.R.; Huschtscha, L.I.; Paul, C.; Song, J.Z.; Stirzaker, C.; Reddel, R.R.; Clark, S.J. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning. *Hum. Mol. Genet.* **2009**, *18*, 3098–3109. [CrossRef]

502. Xiao, Z.; He, Y.; Liu, C.; Xiang, L.; Yi, J.; Wang, M.; Shen, T.; Shen, L.; Xue, Y.; Shi, H.; et al. Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation. *Oncol. Rep.* **2019**, *41*, 2667–2678. [CrossRef]
503. Kim, K.Y.; Lewis, J.S., Jr.; Chen, Z. Current status of clinical testing for human papillomavirus in oropharyngeal squamous cell carcinoma. *J. Pathol. Clin. Res.* **2018**, *4*, 213–226. [CrossRef]

504. Kamijo, T.; Zindy, F.; Roussel, M.F.; Quelle, D.E.; Downing, J.R.; Ashmun, R.A.; Grosveld, G.; Sherr, C.J. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. *Cell* **1997**, *91*, 649–659. [CrossRef]

505. Sharpless, N.E.; Ramsey, M.R.; Balasubramanian, P.; Castrillon, D.H.; Depinho, R.A. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. *Oncogene* **2004**, *23*, 379–385. [CrossRef]

506. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The immunobiology of cancer immunosurveillance and immunoediting. *Immunity* **2004**, *21*, 137–148. [CrossRef]

507. Jhunjhunwala, S.; Hammer, C.; Delamarre, L. Antigen presentation in cancer: Insights into tumour immunogenicity and immune evasion. *Nat. Rev. Cancer* **2021**, *21*, 298–312. [CrossRef]

508. Ritschka, B.; Storer, M.; Mas, A.; Heinzmann, F.; Ortells, M.C.; Morton, J.P.; Sansom, O.J.; Zender, L.; Keyes, W.M. The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. *Genes Dev.* **2017**, *31*, 172–183. [CrossRef]

509. Ohtani, N. Deciphering the mechanism for induction of senescence-associated secretory phenotype (SASP) and its role in aging and cancer development. *J. Biochem.* **2019**, *166*, 289–295. [CrossRef]

510. Wheeler, A.R. *Directive to Prioritize Efforts to Reduce Animal Testing, September 10, 2019*; Memorandum from the US-EPA Administrator to EPA Management; EPA: Washington, DC, USA, 2019.

511. Zhao, E.; Maj, T.; Kryczek, I.; Li, W.; Wu, K.; Zhao, L.; Wei, S.; Crespo, J.; Wan, S.; Vatan, L.; et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. *Nat. Immunol.* **2016**, *17*, 95–103. [CrossRef]

512. Peng, D.; Kryczek, I.; Nagarsheth, N.; Zhao, L.; Wei, S.; Wang, W.; Sun, Y.; Zhao, E.; Vatan, L.; Szeliga, W.; et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. *Nature* **2015**, *527*, 249–253. [CrossRef]

513. Tomasi, T.B.; Magner, W.J.; Khan, A.N. Epigenetic regulation of immune escape genes in cancer. *Cancer Immunol. Immunother.* **2006**, *55*, 1159–1184. [CrossRef]

514. Schnekenburger, M.; Dicato, M.; Diederich, M.F. Anticancer potential of naturally occurring immunoepigenetic modulators: A promising avenue? *Cancer* **2019**, *125*, 1612–1628. [CrossRef]

515. Vijayan, S.; Sidiq, T.; Yousuf, S.; van den Elsen, P.J.; Kobayashi, K.S. Class I transactivator, NLRC5: A central player in the MHC class I pathway and cancer immune surveillance. *Immunogenetics* **2019**, *71*, 273–282. [CrossRef]

516. Chiappinelli, K.B.; Strissel, P.L.; Desrichard, A.; Li, H.; Henke, C.; Akman, B.; Hein, A.; Rote, N.S.; Cope, L.M.; Snyder, A.; et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. *Cell* **2015**, *162*, 974–986. [CrossRef]

517. Axelrod, M.L.; Cook, R.S.; Johnson, D.B.; Balko, J.M. Biological consequences of MHC-II expression by tumor cells in cancer. *Clin. Cancer Res.* **2019**, *25*, 2392–2402. [CrossRef]

518. Kambayashi, T.; Laufer, T.M. Atypical MHC class II-expressing antigen-presenting cells: Can anything replace a dendritic cell? *Nat. Rev. Immunol.* **2014**, *14*, 719–730. [CrossRef] [PubMed]

519. Carey, B.S.; Poulton, K.V.; Poles, A. Factors affecting HLA expression: A review. *Int. J. Immunogenet.* **2019**, *46*, 307–320. [CrossRef] [PubMed]

520. Saigi, M.; Alburquerque-Bejar, J.J.; Sanchez-Cespedes, M. Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: The genetic front. *Oncogene* **2019**, *38*, 5921–5932. [CrossRef]

521. Yoshihama, S.; Vijayan, S.; Sidiq, T.; Kobayashi, K.S. NLRC5/CITA: A key player in cancer immune surveillance. *Trends Cancer* **2017**, *3*, 28–38. [CrossRef] [PubMed]

522. Yoshihama, S.; Roszik, J.; Downs, I.; Meissner, T.B.; Vijayan, S.; Chapuy, B.; Sidiq, T.; Shipp, M.A.; Lizee, G.A.; Kobayashi, K.S. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, 5999–6004. [CrossRef]

523. Ramsuran, V.; Kulkarni, S.; O'hUigin, C.; Yuki, Y.; Augusto, D.G.; Gao, X.; Carrington, M. Epigenetic regulation of differential HLA-A allelic expression levels. *Hum. Mol. Genet.* **2015**, *24*, 4268–4275. [CrossRef]

524. Siebenkas, C.; Chiappinelli, K.B.; Guzzetta, A.A.; Sharma, A.; Jeschke, J.; Vatapalli, R.; Baylin, S.B.; Ahuja, N. Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells. *PLoS ONE* **2017**, *12*, e0179501. [CrossRef]

525. Swets, M.; Seneby, L.; Boot, A.; van Wezel, T.; Gelderblom, H.; van de Velde, C.J.; van den Elsen, P.J.; Kuppen, P.J. Promoter methylation and mRNA expression of HLA-G in relation to HLA-G protein expression in colorectal cancer. *Hum. Immunol.* **2016**, *77*, 764–772. [CrossRef]

526. Taylor, C.T.; Colgan, S.P. Regulation of immunity and inflammation by hypoxia in immunological niches. *Nat. Rev. Immunol.* **2017**, *17*, 774–785. [CrossRef]

527. Garziera, M.; Scarabel, L.; Toffoli, G. Hypoxic modulation of HLA-G expression through the metabolic sensor HIF-1 in human cancer cells. *J. Immunol. Res.* **2017**, 2017, 4587520. [CrossRef]

528. Yaghi, L.; Poras, I.; Simoes, R.T.; Donadi, E.A.; Tost, J.; Daunay, A.; de Almeida, B.S.; Carosella, E.D.; Moreau, P. Hypoxia inducible factor-1 mediates the expression of the immune checkpoint HLA-G in glioma cells through hypoxia response element located in exon 2. *Oncotarget* **2016**, *7*, 63690–63707. [CrossRef]

529. Wijdeven, R.H.; van Luijn, M.M.; Wierenga-Wolf, A.F.; Akkermans, J.J.; van den Elsen, P.J.; Hintzen, R.Q.; Neefjes, J. Chemical and genetic control of IFNgamma-induced MHCII expression. *EMBO Rep.* **2018**, *19*, e45553. [CrossRef]
530. Toor, S.M.; Murshed, K.; Al-Dhaheri, M.; Khawar, M.; Abu Nada, M.; Elkord, E. Immune checkpoints in the tumor microenvironment. *Semin. Cancer Biol.* **2019**, *10*, 2936. [CrossRef]

531. Goltz, D.; Gevensleben, H.; Vogt, T.J.; Dietrich, J.; Golletz, C.; Bootz, F.; Kristiansen, G.; Landsberg, J.; Dietrich, D. CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients. *JCI Insight* **2018**, *3*, e96793. [CrossRef]

532. Chatterjee, A.; Rodger, E.J.; Ahn, A.; Stockwell, P.A.; Parry, M.; Motwani, J.; Gallagher, S.J.; Shklovskaya, E.; Tiffen, J.; Eccles, M.R.; et al. Marked global DNA hypomethylation is associated with constitutive PD-L1 expression in melanoma. *iScience* **2018**, *4*, 312–325. [CrossRef]

533. Wrangle, J.; Wang, W.; Koch, A.; Easwaran, H.; Mohammad, H.P.; Vendetti, F.; Vancriekinge, W.; Demeyer, T.; Du, Z.; Parsana, P.; et al. Alterations of immune response of non-small cell lung cancer with azacytidine. *Oncotarget* **2013**, *4*, 2067–2079. [CrossRef]

534. Li, H.; Chiappinelli, K.B.; Guzzetta, A.A.; Easwaran, H.; Yen, R.W.; Vatapalli, R.; Topper, M.J.; Luo, J.; Connolly, R.M.; Azad, N.S.; et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. *Oncotarget* **2014**, *5*, 587–598. [CrossRef]

535. Darvin, P.; Sasidharan Nair, V.; Elkord, E. PD-L1 expression in human breast cancer stem cells is epigenetically regulated through posttranslational histone modifications. *J. Oncol.* **2019**, *32*, 3958908. [CrossRef]

536. Nair, V.S.; Toor, S.M.; Taha, R.Z.; Shaath, H.; Elkord, E. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. *Clin. Epigenet.* **2018**, *10*, 104. [CrossRef]

537. Nair, V.S.; El Salhat, H.; Taha, R.Z.; John, A.; Ali, B.R.; Elkord, E. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. *Clin. Epigenet.* **2018**, *10*, 78. [CrossRef] [PubMed]

538. Micevic, G.; Thakral, D.; McGeary, M.; Bosenberg, M.W. PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival. *Pigment Cell Melanoma Res.* **2019**, *32*, 435–440. [CrossRef]

539. Xue, G.; Cui, Z.J.; Zhou, X.H.; Zhu, Y.X.; Chen, Y.; Liang, F.J.; Tang, D.N.; Huang, B.Y.; Zhang, H.Y.; Hu, Z.H.; et al. DNA methylation biomarkers predict objective responses to PD-1/PD-L1 inhibition blockade. *Front. Genet.* **2019**, *10*, 724. [CrossRef]

540. Duan, S.; Guo, W.; Xu, Z.; He, Y.; Liang, C.; Mo, Y.; Wang, Y.; Xiong, F.; Guo, C.; Li, Y.; et al. Natural killer group 2D receptor and its ligands in cancer immune escape. *Mol. Cancer* **2019**, *18*, 29. [CrossRef]

541. Raulet, D.H.; Gasser, S.; Gowen, B.G.; Deng, W.; Jung, H. Regulation of ligands for the NKG2D activating receptor. *Annu. Rev. Immunol.* **2013**, *31*, 413–441. [CrossRef]

542. Sanchez-Del-Campo, L.; Marti-Diaz, R.; Montenegro, M.F.; Gonzalez-Guerrero, R.; Hernandez-Caselles, T.; Martinez-Barba, E.; Pinero-Madrona, A.; Cabezas-Herrera, J.; Goding, C.R.; Rodriguez-Lopez, J.N. MITF induces escape from innate immunity in melanoma. *J. Exp. Clin. Cancer Res.* **2021**, *40*, 117. [CrossRef]

543. Ferrari de, A.L.; Tay, R.E.; Pan, D.; Luoma, A.M.; Ito, Y.; Badrinath, S.; Tsoucas, D.; Franz, B.; May, K.F., Jr.; Harvey, C.J.; et al. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. *Science* **2018**, *359*, 1537–1542. [CrossRef]

544. Bhat, J.; Dubin, S.; Dananberg, A.; Quabius, E.S.; Fritsch, J.; Dowds, C.M.; Saxena, A.; Chitadze, G.; Lettau, M.; Kabelitz, D. Histone deacetylase inhibitor modulates NKG2D receptor expression and memory phenotype of human gamma/delta T cells upon interaction with tumor cells. *Front. Immunol.* **2019**, *10*, 569. [CrossRef]

545. Bugide, S.; Green, M.R.; Wajapeeyee, N. Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, E3509–E3518. [CrossRef]

546. Zhang, X.; Rao, A.; Sette, P.; Deibert, C.; Pomerantz, A.; Kim, W.J.; Kohanbash, G.; Chang, Y.; Park, Y.; Engh, J.; et al. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. *Neuro Oncol.* **2016**, *18*, 1402–1412. [CrossRef]

547. Fratta, E.; Coral, S.; Covre, A.; Parisi, G.; Colizzi, F.; Danielli, R.; Nicolay, H.J.; Sigalotti, L.; Maio, M. The biology of cancer testis antigens: Putative function, regulation and therapeutic potential. *Mol. Oncol.* **2011**, *5*, 164–182. [CrossRef]

548. Lian, Y.; Meng, L.; Ding, P.; Sang, M. Epigenetic regulation of MAGE family in human cancer progression-DNA methylation, histone modification, and non-coding RNAs. *Clin. Epigenet.* **2018**, *10*, 115. [CrossRef]

549. Al-Khadairi, G.; Decock, J. Cancer testis antigens and immunotherapy: Where do we stand in the targeting of PRAME? *Cancers* **2019**, *11*, 984. [CrossRef]

550. Gibbs, Z.A.; Whitehurst, A.W. Emerging contributions of cancer/testis antigens to neoplastic behaviors. *Trends Cancer* **2018**, *4*, 701–712. [CrossRef]

551. Fukuyama, T.; Yamazaki, T.; Fujita, T.; Uematsu, T.; Ichiki, Y.; Kaneko, H.; Suzuki, T.; Kobayashi, N. Helicobacter pylori, a carcinogen, induces the expression of melanoma antigen-encoding gene (Mage)-A3, a cancer/testis antigen. *Tumour Biol.* **2012**, *33*, 1881–1887. [CrossRef]

552. Ono, T.; Sato, S.; Kimura, N.; Tanaka, M.; Shibuya, A.; Old, L.J.; Nakayama, E. Serological analysis of BALB/C methylcholanthrene sarcoma Meth A by SEREX: Identification of a cancer/testis antigen. *Int. J. Cancer* **2000**, *88*, 845–851. [CrossRef]

553. Jin, S.; Cao, S.; Grigorev, A.; Li, J.; Meng, Q.; Wang, C.; Feng, M.; Hu, J.; Jiang, F.; Yu, Y. Establishment of cancer/testis antigen profiling based on clinicopathological characteristics in resected pathological stage III non-small cell lung cancer. *Cancer Manag. Res.* **2018**, *10*, 2031–2046. [CrossRef]
554. Kim, Y.D.; Park, H.R.; Song, M.H.; Shin, D.H.; Lee, C.H.; Lee, M.K.; Lee, S.Y. Pattern of cancer/testis antigen expression in lung cancer patients. *Int. J. Mol. Med.* **2012**, *29*, 656–662. [CrossRef]

555. Micalizzi, D.S.; Farabaugh, S.M.; Ford, H.L. Epithelial-mesenchymal transition in cancer: Parallels between normal development and tumor progression. *J. Mammary Gland Biol. Neoplasia* **2010**, *15*, 117–134. [CrossRef]

556. Winograd-Katz, S.E.; Fassler, R.; Geiger, B.; Legate, K.R. The integrin adhésome: From genes and proteins to human disease. *Nat. Rev. Mol. Cell. Biol.* **2014**, *15*, 273–288. [CrossRef]

557. Liu, Q.L.; Luo, M.; Huang, C.; Chen, H.N.; Zhou, Z.G. Epigenetic regulation of epithelial to mesenchymal transition in the cancer metastatic cascade: Implications for cancer therapy. *Front. Oncol.* **2021**, *11*, 657546. [CrossRef]

558. Liu, C.; Fennell, L.J.; Bettington, M.L.; Walker, N.I.; Dwine, J.; Leggett, B.A.; Whitehall, V.L.J. DNA methylation changes that precede onset of dysplasia in advanced sessile serrated adenomas. *Clin. Epigenet.* **2019**, *11*, 90. [CrossRef]

559. Bragelmann, J.; Barahona, P.C.; Marcelin, K.; Roessler, S.; Goeppert, B.; Gallegos, I.; Colombo, A.; Sanhueza, V.; Morales, E.; Rivera, M.T.; et al. Epigenome-wide analysis of methylation changes in the sequence of gallstone disease, dysplasia, and gallbladder cancer. *Hepatology* **2021**, *73*, 2293–2310. [CrossRef]

560. Hernandez-Meza, G.; von Felden, J.; Gonzalez-Kozlova, E.E.; Garcia-Lezana, T.; Peix, J.; Portela, A.; Craig, A.J.; Sayols, S.; Schwartz, M.; Losic, B.; et al. DNA methylation profiling of human hepatocarcinogenesis. *Hepatology* **2020**, *74*, 183. [CrossRef] [PubMed]

561. Han, Q.; Kono, T.J.Y.; Knutson, C.G.; Parry, N.M.; Seiler, C.L.; Fox, J.G.; Tannenbaum, S.R.; Tretyakova, N.Y. Multi-omics characterization of inflammatory bowel disease-induced hyperplasia/dysplasia in the Rag2(−/−)/Il10(−/−) mouse model. *Int. J. Mol. Sci.* **2020**, *22*, 364. [CrossRef] [PubMed]

562. Gougousis, S.; Mouchtaropoulou, E.; Besli, I.; Vrochidis, P.; Skoumpas, I.; Constantinidis, I. HPV-related oropharyngeal cancer and biomarkers based on epigenetics and microbiome profile. *Front. Cell Dev. Biol.* **2020**, *8*, 625330. [CrossRef]

563. Walker, C.; Burggren, W. Remodeling the epigenome and (epi)cytoskeleton: A new paradigm for co-regulation by methylation. *J. Exp. Biol.* **2020**, *223*, jeb220632. [CrossRef]

564. Karki, M.; Jangid, R.K.; Anish, R.; Seervai, R.N.H.; Bertocchio, J.P.; Hotta, T.; Msaouel, P.; Jung, S.Y.; Grimm, S.L.; Coarfa, C.; et al. A cytoskeletal function for PBRM1 reading methylated microtubules. *Sci. Adv.* **2021**, *7*, eabf2866. [CrossRef]

565. Westcott, J.M.; Prechtl, A.M.; Maine, E.A.; Dang, T.T.; Esparza, M.A.; Sun, H.; Zhou, Y.; Xie, Y.; Pearson, G.W. An epigenetically distinct breast cancer cell subpopulation promotes collective invasion. *J. Clin. Investig.* **2015**, *125*, 1927–1943. [CrossRef]

566. Rorth, P. Fellow travellers: Emergent properties of collective cell migration. *EMBO Rep.* **2012**, *13*, 984–991. [CrossRef]

567. Summerbell, E.R.; Mouw, J.K.; Bell, J.S.K.; Knippler, C.M.; Pedro, B.; Arnst, J.L.; Khatib, T.O.; Commander, R.; Barwick, B.G.; Konen, J.; et al. Epigenetically heterogeneous tumor cells direct collective invasion through filopodia-driven fibronectin micropatterning. *Sci. Adv.* **2020**, *6*, eaaz6197. [CrossRef]

568. Grochowski, C.M.; Loomes, K.M.; Spinner, N.B. Jagged1 (JAG1): Structure, expression, and disease associations. *Gene* **2016**, *576*, 381–384. [CrossRef]

569. Yuan, S.; Natesan, R.; Sanchez-Rivera, F.J.; Li, J.; Bhanu, N.V.; Yamazoe, T.; Lin, J.H.; Merrell, A.J.; Sela, Y.; Thomas, S.K.; et al. Global regulation of the histone mark H3K36me2 underlies epithelial plasticity and metastatic progression. *Cancer Discov.* **2020**, *10*, 854–871. [CrossRef]

570. Schneider, J.; Wood, A.; Lee, J.S.; Schuster, R.; Dueker, J.; Maguire, C.; Swanson, S.K.; Florens, L.; Washburn, M.P.; Shilatifard, A. Molecular regulation of histone H3 trimethylation by COMPASS and the regulation of gene expression. *Mol. Cell* **2005**, *19*, 849–856. [CrossRef]

571. Wu, J.; Chai, H.; Xu, X.; Yu, J.; Gu, Y. Histone methyltransferase SETD1A interacts with HIF1alpha to enhance glycolysis and promote cancer progression in gastric cancer. *Mol. Oncol.* **2020**, *14*, 1397–1409. [CrossRef]

572. Wu, J.; Chai, H.; Shan, H.; Pan, C.; Xu, X.; Dong, W.; Yu, J.; Gu, Y. Histone methyltransferase SETD1A induces epithelial-mesenchymal transition to promote invasion and metastasis through epigenetic reprogramming of snail in gastric cancer. *Front. Cell Dev. Biol.* **2021**, *9*, 657888. [CrossRef]

573. Diaz-Lopez, A.; Diaz-Martin, J.; Moreno-Bueno, G.; Cuevas, E.P.; Santos, V.; Olmeda, D.; Portillo, F.; Palacios, J.; Cano, A. Zeb1 and Snail1 engage miR-200f transcriptional and epigenetic regulation during EMT. *Int. J. Cancer* **2015**, *136*, E62–E73. [CrossRef]

574. Cano, A.; Perez-Moreno, M.A.; Rodrigo, I.; Locascio, A.; Blanco, M.J.; del Barrio, M.G.; Portillo, F.; Nieto, M.A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. *Nat. Cell Biol.* **2000**, *2*, 76–83. [CrossRef]

575. Fan, X.; Jin, S.; Li, Y.; Khadaroo, P.A.; Dai, Y.; He, L.; Zhou, D.; Lin, H. Genetic and epigenetic regulation of E-cadherin signaling in human hepatocellular carcinoma. *Cancer Manag. Res.* **2019**, *11*, 8947–8963. [CrossRef]

576. De Santis, G.; Miotti, S.; Mazzi, M.; Canevari, S.; Tomassetti, A. E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells. *Oncogene* **2009**, *28*, 1206–1217. [CrossRef]

577. Padmanaban, V.; Krol, I.; Suhail, Y.; Szczerba, B.M.; Aceto, N.; Bader, J.S.; Ewald, A.J. E-cadherin is required for metastasis in multiple models of breast cancer. *Nature* **2019**, *573*, 439–444. [CrossRef]

578. Nardone, V.; Lucarelli, A.P.; Dalle, V.A.; Fanelli, R.; Tomassetti, A.; Belvisi, L.; Civera, M.; Parisini, E. Crystal structure of human E-cadherin-EC1EC2 in complex with a peptidomimetic competitive inhibitor of cadherin homophilic interaction. *J. Med. Chem.* **2016**, *59*, 5089–5094. [CrossRef]
579. Lee, S.; Lee, H.J.; Kim, J.H.; Lee, H.S.; Jang, J.J.; Kang, G.H. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. *Am. J. Pathol.* **2003**, *163*, 1371–1378. [CrossRef]

580. Dumont, N.; Wilson, M.B.; Crawford, Y.G.; Reynolds, P.A.; Sigaroudinia, M.; Tlsty, T.D. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 14867–14872. [CrossRef]

581. Tsujiuchi, T.; Shimizu, K.; Itsuzaki, Y.; Onishi, M.; Sugata, E.; Fujii, H.; Honoki, K. CpG site hypermethylation of E-cadherin and Connexin26 genes in hepatocellular carcinomas induced by a choline-deficient L-Amino Acid-defined diet in rats. *Mol. Carcinog.* **2007**, *46*, 269–274. [CrossRef]

582. Feng, W.; Shen, L.; Wen, S.; Rosen, D.G.; Jelinek, J.; Hu, X.; Huan, S.; Huang, M.; Liu, J.; Sahin, A.A.; et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. *Breast Cancer Res.* **2007**, *9*, R57. [CrossRef]

583. Collado, M.; Serrano, M. Senescence in tumours: Evidence from mice and humans. *Nat. Rev. Cancer* **2010**, *10*, 51–57. [CrossRef]

584. Collado, M.; Blasco, M.A.; Serrano, M. Cellular senescence in cancer and aging. *Cell* **2007**, *130*, 223–233. [CrossRef]

585. de Lange, T. Shelterin-mediated telomere protection. *Annu. Rev. Genet.* **2018**, *52*, 223–247. [CrossRef]

586. Stroik, S.; Hendrickson, E.A. Telomere fusions and translocations: A bridge too far? *Curr. Opin. Genet. Dev.* **2020**, *60*, 85–91. [CrossRef]

587. Maciejowski, J.; de Lange, T. Telomeres in cancer: Tumour suppression and genome instability. *Nat. Rev. Mol. Cell Biol.* **2017**, *18*, 175–186. [CrossRef]

588. Herate, C.; Sabatier, L. Telomere instability initiates and then boosts carcinogenesis by the butterfly effect. *Curr. Opin. Genet. Dev.* **2020**, *60*, 92–98. [CrossRef]

589. Cesare, A.J.; Karlseder, J. A three-state model of telomere control over human proliferative boundaries. *Curr. Opin. Cell Biol.* **2012**, *24*, 731–738. [CrossRef] [PubMed]

590. Kolquist, K.A.; Ellisen, L.W.; Counter, C.M.; Meyerson, M.; Tan, L.K.; Weinberg, R.A.; Haber, D.A.; Gerald, W.L. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. *Nat. Genet.* **1998**, *19*, 182–186. [CrossRef] [PubMed]

591. Lee, D.D.; Komosa, M.; Nunes, N.M.; Tabori, U. DNA methylation of the TERT promoter and its impact on human cancer. *Curr. Opin. Genet. Dev.* **2020**, *60*, 17–24. [CrossRef] [PubMed]

592. Lee, D.D.; Leao, R.; Komosa, M.; Gallo, M.; Zhang, C.H.; Lipman, T.; Remke, M.; Heidari, A.; Nunes, N.M.; Apolonio, J.D.; et al. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. *J. Clin. Investig.* **2019**, *129*, 223–229. [CrossRef] [PubMed]

593. Toubiana, S.; Selig, S. Human subtelomeric DNA methylation: Regulation and roles in telomere function. *Curr. Opin. Genet. Dev.* **2020**, *60*, 9–16. [CrossRef]

594. Silva, B.; Arora, R.; Bione, S.; Azzalin, C.M. TERRA transcription destabilizes telomere integrity to initiate break-induced replication in human ALT cells. *Nat. Commun.* **2021**, *12*, 3760. [CrossRef] [PubMed]

595. Feretzaki, M.; Pospisilova, M.; Valador, F.R.; Lunardi, T.; Krejci, L.; Lingner, J. RAD51-dependent recruitment of TERRA lncRNA to telomeres through R-loops. *Nature* **2020**, *587*, 303–308. [CrossRef] [PubMed]

596. Campbell, P.J.; Getz, G. Pan-cancer analysis of whole genomes. *Nature* **2020**, *578*, 82–93.

597. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell* **1996**, *86*, 353–364. [CrossRef]

598. Folkman, J. What is the evidence that tumors are angiogenesis dependent? *J. Natl. Cancer Inst.* **1990**, *82*, 4–6. [CrossRef]

599. Kaur, S.; Bronson, S.M.; Pal-Nath, D.; Miller, T.W.; Soto-Pantoja, D.R.; Roberts, D.D. Functions of thrombospondin-1 in the tumor microenvironment. *Int. J. Mol. Sci.* **2021**, *22*, 4570. [CrossRef] [PubMed]

600. Perez-Janices, N.; Blanco-Luquin, I.; Tunon, M.T.; Barba-Ramos, E.; Ibanez, B.; Zazpe-Cenoz, I.; Martinez-Aguillo, M.; Hernandez, B.; Martinez-Lopez, E.; Fernandez, A.F.; et al. EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas. *Oncotarget* **2015**, *6*, 368–380. [CrossRef] [PubMed]

601. Watnick, R.S.; Rodriguez, R.K.; Wang, S.; Blois, A.L.; Rangarajan, A.; Ince, T.; Weinberg, R.A. Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells. *Oncogene* **2015**, *34*, 2823–2835. [CrossRef]

602. Goncalves, C.S.; Le, B.E.; Arnaud, P.; Costa, B.M. HOX gene cluster (de)regulation in brain: From neurodevelopment to malignant glial tumours. *Cell Mol. Life Sci.* **2020**, *77*, 3797–3821. [CrossRef]

603. Smith, J.; Zyoud, A.; Allegrucci, C. A case of identity: HOX genes in normal and cancer stem cells. *Cancers* **2019**, *11*, 512. [CrossRef]

604. Le Boiteux, E.; Court, F.; Guichet, P.O.; Vaurs-Barriere, C.; Vaillant, I.; Chautard, E.; Verrelle, P.; Costa, B.M.; Karayan-Tapon, L.; Fogli, A.; et al. Widespread overexpression from the four DNA hypermethylated HOX clusters in aggressive (IDHwt) glioma is associated with H3K27me3 depletion and alternative promoter usage. *Mol. Oncol.* **2021**, *15*, 1995–2010. [CrossRef]

605. Louis, D.N.; Perry, A.; Reifenberger, G.; von, D.A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.; Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. *Acta Neuropathol.* **2016**, *131*, 803–820. [CrossRef]

606. Li, H.H.; Chen, R.; Hyduke, D.R.; Williams, A.; Frotschl, R.; Ellinger-Ziegelbauer, H.; O'Lone, R.; Yauk, C.L.; Aubrecht, J.; Fornace, A.J., Jr. Development and validation of a high-throughput transcriptomic biomarker to address 21st century genetic toxicology needs. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, E10881–E10889. [CrossRef] [PubMed]
607. Geiss, G.K.; Bumgarner, R.E.; Birditt, B.; Dahl, T.; Dowidar, N.; Dunaway, D.L.; Fell, H.P.; Ferree, S.; George, R.D.; Grogan, T.; et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. *Nat. Biotechnol.* **2008**, *26*, 317–325. [CrossRef]

608. Chappell, G.A.; Rager, J.E. Epigenetics in chemical-induced genotoxic carcinogenesis. *Curr. Opin. Toxicol.* **2017**, *6*, 10–17. [CrossRef]

609. Mascolo, M.G.; Perdichizzi, S.; Vaccari, M.; Rotondo, F.; Zanzi, C.; Grilli, S.; Paparella, M.; Jacobs, M.N.; Colacci, A. The transformics assay: First steps for the development of an integrated approach to investigate the malignant cell transformation in vitro. *Carcinogenesis* **2018**, *39*, 955–967. [CrossRef]

610. Benigni, R.; Bossa, C.; Tcheremenskaia, O. Nongenotoxic carcinogenicity of chemicals: Mechanisms of action and early recognition through a new set of structural alerts. *Chem. Rev.* **2013**, *113*, 2940–2957. [CrossRef] [PubMed]

611. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* **2006**, *126*, 663–676. [CrossRef] [PubMed]

612. Petrov, A.I.; Kay, S.J.E.; Kalvari, I.; Howe, K.L.; Gray, K.A.; Bruford, E.A.; Kersey, P.J.; Cochrane, G.; Finn, R.D.; Bateman, A.; et al. RNAcentral: A comprehensive database of non-coding RNA sequences. *Nucleic Acids Res.* **2017**, *45*, D128–D134. [PubMed]

613. Quek, X.C.; Thomson, D.W.; Maag, J.L.; Bartonicek, N.; Signal, B.; Clark, M.B.; Gloss, B.S.; Dinger, M.E. lncRNAdb v2.0: Expanding the reference database for functional long noncoding RNAs. *Nucleic Acids Res.* **2015**, *43*, D168–D173. [CrossRef]

614. House, J.S.; Grimm, F.A.; Jima, D.D.; Zhou, Y.H.; Rusyn, I.; Wright, F.A. A pipeline for high-throughput concentration response modeling of gene expression for toxicogenomics. *Front. Genet.* **2017**, *8*, 168. [CrossRef]

615. Larman, H.B.; Scott, E.R.; Wogan, M.; Oliveira, G.; Torkamani, A.; Schultz, P.G. Sensitive, multiplex and direct quantification of RNA sequences using a modified RASL assay. *Nucleic Acids Res.* **2014**, *42*, 9146–9157. [CrossRef]

616. Grimm, F.A.; Iwata, Y.; Sirenko, O.; Chappell, G.A.; Wright, F.A.; Reif, D.M.; Braisted, J.; Gerhold, D.L.; Yeakley, J.M.; Shepard, P.; et al. A chemical-biological similarity-based grouping of complex substances as a prototype approach for evaluating chemical alternatives. *Green Chem.* **2016**, *18*, 4407–4419. [CrossRef]

617. Kurdyukov, S.; Bullock, M. DNA methylation analysis: Choosing the right method. *Biology* **2016**, *5*, 3. [CrossRef]

618. Asmus, N.; Papale, L.A.; Madrid, A.; Alisch, R.S. Simultaneous targeted methylation sequencing (sTM-Seq). *Curr. Protoc. Hum. Genet.* **2019**, *101*, e81. [CrossRef]

619. Kagohara, L.T.; Stein-O'Brien, G.L.; Kelley, D.; Flam, E.; Wick, H.C.; Danilova, L.V.; Easwaran, H.; Favorov, A.V.; Qian, J.; Gaykalova, D.A.; et al. Epigenetic regulation of gene expression in cancer: Techniques, resources and analysis. *Brief Funct. Genom.* **2018**, *17*, 49–63. [CrossRef]

620. Wiehle, L.; Thorn, G.J.; Raddatz, G.; Clarkson, C.T.; Rippe, K.; Lyko, F.; Breiling, A.; Teif, V.B. DNA (de)methylation in embryonic stem cells controls CTCF-dependent chromatin boundaries. *Genome Res.* **2019**, *29*, 750–761. [CrossRef]

621. Canzio, D.; Nwakeze, C.L.; Horta, A.; Rajkumar, S.M.; Coffey, E.L.; Duffy, E.E.; Duffie, R.; Monahan, K.; O'Keeffe, S.; Simon, M.D.; et al. Antisense lncRNA transcription mediates DNA demethylation to drive stochastic protocadherin alpha promoter choice. *Cell* **2019**, *177*, 639–653. [CrossRef]

622. Mohni, K.N.; Wessel, S.R.; Zhao, R.; Wojciechowski, A.C.; Luzwick, J.W.; Layden, H.; Eichman, B.F.; Thompson, P.S.; Mehta, K.P.M.; Cortez, D. HMCES maintains genome integrity by shielding abasic sites in single-strand DNA. *Cell* **2019**, *176*, 144–153. [CrossRef]

623. Mahmood, N.; Rabbani, S.A. DNA methylation readers and cancer: Mechanistic and therapeutic applications. *Front. Oncol.* **2019**, *9*, 489. [CrossRef]

624. Ip, J.P.K.; Mellios, N.; Sur, M. Rett syndrome: Insights into genetic, molecular and circuit mechanisms. *Nat. Rev. Neurosci.* **2018**, *19*, 368–382. [CrossRef]

625. Mellen, M.; Ayata, P.; Heintz, N. 5-hydroxymethylcytosine accumulation in postmitotic neurons results in functional demethylation of expressed genes. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, E7812–E7821. [CrossRef]

626. Booth, M.J.; Ost, T.W.; Beraldi, D.; Bell, N.M.; Branco, M.R.; Reik, W.; Balasubramanian, S. Oxidative bisulfite sequencing of 5-methylcytosine and 5-hydroxymethylcytosine. *Nat. Protoc.* **2013**, *8*, 1841–1851. [CrossRef]

627. Liu, Y.; Siejka-Zielinska, P.; Velikova, G.; Bi, Y.; Yuan, F.; Tomkova, M.; Bai, C.; Chen, L.; Schuster-Bockler, B.; Song, C.X. Bisulfite-free direct detection of 5-methylcytosine and 5-hydroxymethylcytosine at base resolution. *Nat. Biotechnol.* **2019**, *37*, 424–429. [CrossRef]

628. Yu, M.; Hon, G.C.; Szulwach, K.E.; Song, C.X.; Zhang, L.; Kim, A.; Li, X.; Dai, Q.; Shen, Y.; Park, B.; et al. Base-resolution analysis of 5-hydroxymethylcytosine in the Mammalian genome. *Cell* **2012**, *149*, 1368–1380. [CrossRef]

629. Tierling, S.; Schmitt, B.; Walter, J. Comprehensive evaluation of commercial bisulfite-based DNA methylation kits and development of an alternative protocol with improved conversion performance. *Genet. Epigenet.* **2018**, *10*, 1179237X18766097. [CrossRef]

630. Paparella, M.; Colacci, A.; Jacobs, M.N. Uncertainties of testing methods: What do we (want to) know about carcinogenicity? *ALTEX* **2017**, *34*, 235–252. [CrossRef]

631. Cohen, S.M. The relevance of experimental carcinogenicity studies to human safety. *Curr. Opin. Toxicol.* **2017**, *3*, 6–11. [CrossRef]

632. Goodman, J.I. Goodbye to the bioassay. *Toxicol. Res.* **2018**, *7*, 558–564. [CrossRef]

633. Sarigiannis, D.A.; Karakitsios, S.; Dominguez-Romero, E.; Papadaki, K.; Brochot, C.; Kumar, V.; Schumacher, M.; Sy, M.; Mielke, H.; Greiner, M.; et al. Physiology-based toxicokinetic modelling in the frame of the European Human Biomonitoring Initiative. *Environ. Res.* **2019**, *172*, 216–230. [CrossRef]
634. OECD. Guidance Document on the Characterisation, Validation and Reporting of PBK Models for Regulatory Purposes; Series on Testing and Assessment, no. 331; Environment Directorate; Organisation for Economic Cooperation and Development: Paris, France, 2021; pp. 1–96.

635. Cheong, A.; Zhang, X.; Cheung, Y.Y.; Tang, W.Y.; Chen, J.; Ye, S.H.; Medvedovic, M.; Leung, Y.K.; Prins, G.S.; Ho, S.M. DNA methylome changes by estradiol benzoate and bisphenol A links early-life environmental exposures to prostate cancer risk. *Epigenetics* **2016**, *11*, 674–689. [CrossRef]

636. Aravind, L.; Abhiman, S.; Iyer, L.M. Natural history of the eukaryotic chromatin protein methylation system. *Prog. Mol. Biol. Transl. Sci.* **2011**, *101*, 105–176.

637. Iyer, L.M.; Abhiman, S.; Aravind, L. Natural history of eukaryotic DNA methylation systems. *Prog. Mol. Biol. Transl. Sci.* **2011**, *101*, 25–104.

638. Angrish, M.M.; Allard, P.; McCullough, S.D.; Druwe, I.L.; Helbling, C.L.; Hines, E.; Chorley, B.N. Epigenetic applications in adverse outcome pathways and environmental risk evaluation. *Environ. Health Perspect.* **2018**, *126*, 045001. [CrossRef]

639. Wirbisky-Hershberger, S.E.; Sanchez, O.F.; Horzmann, K.A.; Thanki, D.; Yuan, C.; Freeman, J.L. Atrazine exposure decreases the activity of DNMTs, global DNA methylation levels, and dnmt expression. *Food Chem. Toxicol.* **2017**, *109*, 727–734. [CrossRef]

640. Sugai, T.; Yoshida, M.; Eizuka, M.; Uesugii, N.; Habano, W.; Otsuka, K.; Sasaki, A.; Yamamoto, E.; Matsumoto, T.; Suzuki, H. Analysis of the DNA methylation level of cancer-related genes in colorectal cancer and the surrounding normal mucosa. *Clin. Epigenet.* **2017**, *9*, 55. [CrossRef]

641. Lim, P.L.; Tan, W.; Latchoumycandane, C.; Mok, W.C.; Khoo, Y.M.; Lee, H.S.; Sattabongkot, J.; Beerheide, W.; Lim, S.G.; Tan, T.M.; et al. Molecular and functional characterization of drug-metabolizing enzymes and transporter expression in the novel spontaneously immortalized human hepatocyte line HC-04. *Toxicol. Vitro* **2007**, *21*, 1390–1401. [CrossRef]

642. Kleensang, A.; Vantangoli, M.M.; Odwin-Dacosta, S.; Andersen, M.E.; Boekelheide, K.; Bouhifd, M.; Fornace, A.J., Jr.; Li, H.H.; Livi, C.B.; Madnick, S.; et al. Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function. *Sci. Rep.* **2016**, *6*, 28994. [CrossRef]

643. Horvath, P.; Aulner, N.; Bickle, M.; Davies, A.M.; Nery, E.D.; Ebner, D.; Montoya, M.C.; Ostling, P.; Pietiainen, V.; Price, L.S.; et al. Screening out irrelevant cell-based models of disease. *Nat. Rev. Drug Discov.* **2016**, *15*, 751–769. [CrossRef]

644. Gerecke, C.; Schumacher, F.; Edlich, A.; Wetzel, A.; Yealland, G.; Neubert, L.K.; Scholtka, B.; Homann, T.; Kleuser, B. Vitamin C promotes decitabine or azacytidine induced DNA hydroxymethylation and subsequent reactivation of the epigenetically silenced tumour suppressor CDKN1A in colon cancer cells. *Oncotarget* **2018**, *9*, 32822–32840. [CrossRef]

645. Schock, B.C.; Koostra, J.; Kwack, S.; Hackman, R.M.; Van Der Vliet, A.; Cross, C.E. Ascorbic acid in nasal and tracheobronchial airway lining fluids. *Free Radic. Biol. Med.* **2004**, *37*, 1393–1401. [CrossRef]

646. Padayatty, S.J.; Levine, M. Vitamin C: The known and the unknown and Goldilocks. *Oral Dis.* **2016**, *22*, 463–493. [CrossRef]

647. Jiang, J.; Wolters, J.E.; van Breda, S.G.; Kleinjans, J.C.; de Kok, T.M. Development of novel tools for the in vitro investigation of drug-induced liver injury. *Expert Opin. Drug Metab. Toxicol.* **2015**, *11*, 1523–1537. [CrossRef]

648. Li, M.; Li, X.; Zhuang, Y.; Flemington, E.K.; Lin, Z.; Shan, B. Induction of a novel isoform of the lncRNA HOTAIR in Claudin-low breast cancer cells attached to extracellular matrix. *Mol. Oncol.* **2017**, *11*, 1698–1710. [CrossRef] [PubMed]

649. Wolters, J.E.J.; van Breda, S.G.J.; Caiment, F.; Claessen, S.M.; de Kok, T.M.C.M.; Kleinjans, J.C.S. Nuclear and mitochondrial DNA methylation patterns induced by valproic acid in human hepatocytes. *Chem. Res. Toxicol.* **2017**, *30*, 1847–1854. [CrossRef] [PubMed]

650. Wolters, J.E.J.; van Breda, S.G.J.; Grossmann, J.; Fortes, C.; Caiment, F.; Kleinjans, J.C.S. Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. *Toxicol. Lett.* **2018**, *289*, 1–13. [CrossRef] [PubMed]